Filing Analysis
Protalix BioTherapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026, and provided a business/clinical update.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2026
- Filing date: August 12, 2026
- The filing includes a press release (Exhibit 99.1) containing financial results and clinical updates.
Protalix BioTherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 25, 2026. Shareholders approved the election of eight directors, ratified the appointment of Kesselman & Kesselman as independent auditors, and approved an increase in shares available under the 2006 Stock Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 25, 2026, in Tel Aviv, Israel.
- Eight directors were elected to the Board of Directors.
- Shareholders approved an increase in the 2006 Stock Incentive Plan from 17,475,171 to 20,975,171 shares available for issuance.
- Kesselman & Kesselman (PwC member) was ratified as independent auditor for fiscal year ending Dec 31, 2026.
- Non-binding advisory vote on executive compensation was approved.
Protalix BioTherapeutics, Inc. filed a Form 8-K to announce that it has posted its May 2026 corporate presentation to its website.
📋 Key Facts
- On May 21, 2026, the company posted its corporate presentation to its website.
- The presentation is furnished as Exhibit 99.1 to the Current Report.
- The filing is submitted under Item 7.01 (Regulation FD Disclosure) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Protalix BioTherapeutics announced its financial results for the first quarter ended March 31, 2026, along with business and clinical updates. The information was provided via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2026
- Provided a business and clinical update in the accompanying press release (Exhibit 99.1)
- The report was filed under Item 2.02, Results of Operations and Financial Condition
- The filing date is May 13, 2026
Protalix BioTherapeutics announced its financial results for the fiscal year ended December 31, 2025, and provided a business and clinical update.
📋 Key Facts
- The filing was made on March 18, 2026, to report results for the fiscal year ended December 31, 2025.
- The company furnished a press release as Exhibit 99.1 containing the financial data and clinical updates.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Protalix BioTherapeutics announced that the European Commission has approved a new 2 mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® (pegunigalsidase alfa). This approval provides an additional dosing option for adults living with Fabry disease who are stable on Enzyme Replacement Therapy.
📋 Key Facts
- On March 9, 2026, the European Commission (EC) approved a 2 mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®.
- The approval is specifically for adults living with Fabry disease who are stable with an Enzyme Replacement Therapy (ERT).
- The EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
- Elfabrio® is being commercialized in partnership with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A.
Protalix BioTherapeutics, Inc. has filed an 8-K to furnish a corporate presentation via its website in accordance with Regulation FD.
📋 Key Facts
- The company posted a new corporate presentation to its website on February 11, 2026.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- Information provided in the presentation is furnished, not filed, meaning it is exempt from certain liabilities under Section 18 of the Exchange Act.
Protalix BioTherapeutics announced a positive opinion from the EMA's CHMP regarding its product Elfabrio. The recommendation supports a new dosing regimen (2 mg/kg every-4-weeks) for adult Fabry disease patients stable on ERT.
📋 Key Facts
- EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on January 30, 2026.
- The recommendation concerns the Elfabrio® dosing regimen: 2 mg/kg every-4-weeks (E4W).
- Target population: Adult Fabry disease patients stable with an ERT (Enzyme Replacement Therapy) treatment.
- The announcement was made in partnership with Chiesi Global Rare Diseases.
Protalix BioTherapeutics, Inc. filed an 8-K to furnish a press release and a letter to stockholders issued on January 5, 2026, pursuant to Regulation FD.
📋 Key Facts
- The filing was made on January 5, 2026.
- The company is providing a copy of a stockholder letter via Exhibit 99.1.
- Information in the report is furnished under General Instruction B.2 and is not 'filed' for purposes of Section 18 liability.
Protalix BioTherapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025, and provided a business and clinical update.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2025
- Filing date: November 13, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and clinical updates.
- The report was signed by Dror Bashan, President and CEO.
Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases have requested a re-examination of a negative opinion from the EMA's CHMP regarding the dosing regimen for Elfabrio. The disagreement centers on the proposed 2 mg/kg body weight infusion every 4 weeks (E4W) dosing schedule.
🚩 Red Flags
- Regulatory setback: Negative opinion from the EMA's CHMP regarding a key dosing regimen for their lead product Elfabrio.
- Potential delay in commercialization or market uptake if the re-examination is unsuccessful.
📋 Key Facts
- Company and partner Chiesi Global Rare Diseases requested a re-examination of a negative CHMP opinion.
- The issue concerns the Elfabrio® (pegunigalsidase alfa) proposed dosing regimen: 2 mg/kg body weight infused every 4 weeks (E4W).
- The filing was made on November 3, 2025.
Protalix BioTherapeutics announced that the EMA's Committee for Medicinal Products for Human Use issued a negative opinion regarding a proposed dosing regimen change for its product Elfabrio (pegunigalsidase alfa). The request sought to move from a 1 mg/kg infusion every 2 weeks to a 2 mg/kg infusion every 4 weeks.
🚩 Red Flags
- Negative regulatory opinion on a key product dosing regimen, which could impact commercial uptake and patient compliance.
- Potential delay or failure in optimizing the commercial profile of Elfabrio.
📋 Key Facts
- Date of event: October 17, 2025
- Regulatory Body: EMA Committee for Medicinal Products for Human Use (CHMP)
- Product: Elfabrio (pegunigalsidase alfa)
- Nature of Event: Negative opinion on a request to change dosing regimen from 1 mg/kg every 2 weeks to 2 mg/kg every 4 weeks
- Partner involved: Chiesi Global Rare Diseases (Chiesi Farmaceutici S.p.A.)
Protalix BioTherapeutics, Inc. has amended its existing 'At The Market' (ATM) equity offering agreement with H.C. Wainwright & Co., LLC. This amendment is a technical update to reflect the effectiveness of a new Form S-3 registration statement.
🚩 Red Flags
- Potential for future dilution via the ATM offering mechanism.
📋 Key Facts
- Date of Amendment: August 22, 2025
- Counterparty: H.C. Wainwright & Co., LLC (Sales Agent)
- Purpose: To modify the Sales Agreement to reflect the effectiveness of a new Form S-3 registration statement (Registration No. 333-286802).
- Mechanism: The amendment pertains to an 'at-the-market' equity offering program for common stock.
Protalix BioTherapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025, and provided a business and clinical update.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2025
- Filing date: August 14, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and clinical updates.
Protalix BioTherapeutics announced the dismissal of a stockholder class action lawsuit regarding alleged violations in its amended bylaws. The matter was resolved via a stipulation where the company agreed to pay $160,000 in legal fees to the plaintiff's counsel.
🚩 Red Flags
- Legal settlement involving bylaws/corporate governance (though resolved)
📋 Key Facts
- Dismissal of Verified Stockholder Class Action Complaint (Thomas v. Bashan, et al.)
- The lawsuit alleged that amended bylaws violated 8 Del. C. §§ 141(k) & 228(a)
- Company agreed to pay $160,000 in fees and expenses to Plaintiff's counsel (Fields Kupka & Shukurov LLP)
- The dismissal is 'with prejudice' only as to the plaintiff
- Resolution achieved through an amendment of the Bylaws on May 8, 2025
Protalix BioTherapeutics announced the appointment of Gilad Mamlok as Senior Vice President and CFO, effective August 24, 2025. He succeeds Eyal Rubin, who is transitioning out following a prior resignation notice.
🚩 Red Flags
- Succession event: The CFO is being replaced, though the company has implemented a transition period to mitigate risk.
📋 Key Facts
- Gilad Mamlok appointed as SVP and CFO, effective August 24, 2025.
- Eyal Rubin (current CFO) will remain available to the company until October 2025 to ensure transition.
- Mamlok's compensation includes a monthly base salary of ~81,000 NIS (~$24,066).
- Mamlok granted options to purchase 597,990 shares at an exercise price of $1.45 (based on the last trading day prior to grant date).
- Options vest over a three-year period in equal quarterly increments with full acceleration upon change of control.
Protalix BioTherapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 26, 2025. The meeting resulted in the election of eight directors and the ratification of Kesselman & Kesselman as independent auditors.
🚩 Red Flags
- Significant number of 'Broker Non-Votes' (12,683,549) across all director elections suggests a large portion of shares were not voted on these specific matters, though this is common in micro-cap/biotech structures.
📋 Key Facts
- Annual Meeting held on June 26, 2025, in Tel Aviv, Israel.
- Eight nominees were elected to the Board of Directors, including Eliot Richard Forster, Ph.D., Dror Bashan, and Amos Bar Shalev.
- Stockholders approved the compensation of named executive officers on a non-binding, advisory basis (Say-on-Pay).
- Kesselman & Kesselman (Member of PwC International Limited) was ratified as the independent auditor for fiscal year 2025.
Protalix BioTherapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025, and provided a business and clinical update.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- Includes both financial results and clinical updates via Exhibit 99.1
- Filed under Item 2.02 (Results of Operations and Financial Condition)
Protalix BioTherapeutics, Inc. announced that CFO Eyal Rubin has provided six months' notice of his resignation to pursue other opportunities. The departure includes a structured transition period and a significant severance package.
🚩 Red Flags
- Departure of a long-tenured CFO (nearly six years) can signal internal shifts or strategic changes.
- Significant cash/equity outflow via accelerated vesting and extended severance payments.
📋 Key Facts
- Eyal Rubin (Sr. VP and CFO) resigned on April 21, 2025.
- The resignation includes a six-month notice period for transition services.
- Severance package includes full salary/benefits for the 6-month notice period plus an additional two months' salary upon departure.
- Full accelerated vesting of all outstanding unvested equity-based incentives is included in the severance agreement.
Protalix BioTherapeutics, Inc. has amended its existing At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to increase the aggregate gross sales price by $20,000,000. The company intends to use these proceeds for general corporate purposes, including working capital and funding clinical trials.
🚩 Red Flags
- Increased equity overhang: The $20M increase in ATM capacity suggests a need for immediate liquidity, which typically results in shareholder dilution.
📋 Key Facts
- Amendment to At-The-Market (ATM) Offering Agreement dated February 27, 2023.
- Increase in aggregate gross sales price of $20,000,000.
- Sales Agent: H.C. Wainwright & Co., LLC.
- Proceeds intended for general corporate purposes, working capital, and clinical trial funding.
- Shares to be issued under existing shelf registration statement on Form S-3 (No. 333-264394).
Protalix BioTherapeutics, Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.
📋 Key Facts
- Announcement of FY 2024 financial results (ended Dec 31, 2024).
- Provision of a business and clinical update via press release dated March 17, 2025.
- Filing made pursuant to Item 2.02 (Results of Operations and Financial Condition).
Protalix BioTherapeutics, Inc. has amended and restated its Bylaws, effective December 27, 2024. The changes primarily focus on strengthening corporate governance by increasing the threshold for stockholders to call special meetings and establishing exclusive legal forums.
🚩 Red Flags
- Increased threshold for special meetings (10% to 25%) makes it significantly harder for activist investors to force a meeting.
- Removal of stockholder written consent rights reduces shareholder power relative to the Board.
📋 Key Facts
- Board of Directors unanimously approved and adopted Amended and Restated Bylaws on December 27, 2024.
- Increased stockholder ownership requirement for calling special meetings from 10% to 25%.
- Extended the timeframe for the Company's secretary to fix a special meeting date from 10 days to at least 30 days after request.
- Removed the provision allowing stockholders to act by written consent in lieu of a meeting.
- Established Delaware Court of Chancery as the exclusive forum for state corporate litigation and U.S. federal district courts for Securities Act claims.
Protalix BioTherapeutics, Inc. filed an 8-K to furnish a press release and a letter addressed to stockholders dated December 23, 2024. The filing is made pursuant to Regulation FD disclosure requirements.
📋 Key Facts
- The company issued a press release containing a stockholder letter on December 23, 2024.
- The information provided under Item 7.01 is furnished rather than filed, meaning it is not subject to the liability of Section 18 of the Exchange Act.
- The filing includes Exhibit 99.1 (Press Release).
Protalix BioTherapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024, and provided a business/clinical update.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business/clinical updates.
Protalix BioTherapeutics announced that data from its Phase I clinical trial of PRX-115, a treatment for uncontrolled gout, will be presented at the ACR Convergence 2024 conference in November.
📋 Key Facts
- Company to present Phase I clinical trial data for PRX-115 (recombinant PEGylated uricase) at ACR Convergence 2024.
- The presentation is scheduled as a late-breaking poster from November 14-19, 2024.
- Data focuses on prolonged plasma urate lowering after a single intravenous administration of PRX-115.
Protalix BioTherapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024, and provided a general business update.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024
- Filing date: August 14, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
Protalix BioTherapeutics, Inc. held its 2023 Annual Meeting of Stockholders on June 27, 2024. The meeting resulted in the election of seven directors and the ratification of Kesselman & Kesselman as independent auditors for fiscal year 2024.
🚩 Red Flags
- Significant 'Against' votes on executive compensation (approx. 9.8M against vs 17M for) and the Stock Incentive Plan (approx. 10.3M against vs 16.9M for), indicating notable shareholder dissent regarding dilution or pay structures.
📋 Key Facts
- The 2023 Annual Meeting was held on June 27, 2024.
- Seven nominees were elected to the Board of Directors.
- Stockholders approved amendments to the 2006 Stock Incentive Plan, increasing available shares from 12,475,171 to 17,475,171.
- Kesselman & Kesselman (Member of PwC International Limited) was ratified as independent auditors for FY2024.
- Executive compensation was approved on a non-binding advisory basis.
Protalix BioTherapeutics, Inc. issued an 8-K to announce its financial results for the fiscal year ended March 31, 2024, and provided a general business update via press release.
📋 Key Facts
- Reporting period: Fiscal year ended March 31, 2024.
- Announcement date: May 10, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results and business updates.
Protalix BioTherapeutics, Inc. issued an 8-K to announce its fiscal year 2023 financial results and provide a general business update via press release.
📋 Key Facts
- Report date: March 14, 2024
- Covers financial results for the fiscal year ended December 31, 2023
- Includes a business update as part of the earnings announcement